Your browser doesn't support javascript.
loading
Identification of BiP as a CB1 Receptor-Interacting Protein That Fine-Tunes Cannabinoid Signaling in the Mouse Brain.
Costas-Insua, Carlos; Moreno, Estefanía; Maroto, Irene B; Ruiz-Calvo, Andrea; Bajo-Grañeras, Raquel; Martín-Gutiérrez, David; Diez-Alarcia, Rebeca; Vilaró, M Teresa; Cortés, Roser; García-Font, Nuria; Martín, Ricardo; Espina, Marc; Botta, Joaquín; Ginés, Silvia; McCormick, Peter J; Sánchez-Prieto, José; Galve-Roperh, Ismael; Mengod, Guadalupe; Urigüen, Leyre; Marsicano, Giovanni; Bellocchio, Luigi; Canela, Enric I; Casadó, Vicent; Rodríguez-Crespo, Ignacio; Guzmán, Manuel.
Afiliação
  • Costas-Insua C; Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas, Madrid, 28031, Spain.
  • Moreno E; Department of Biochemistry and Molecular Biology, Instituto Universitario de Investigación Neuroquímica, Complutense University, Madrid, 28040, Spain.
  • Maroto IB; Instituto Ramón y Cajal de Investigación Sanitaria, Madrid, 28034, Spain.
  • Ruiz-Calvo A; Department of Biochemistry and Molecular Biomedicine, Faculty of Biology, Institute of Biomedicine of the University of Barcelona, University of Barcelona, Barcelona, 08028, Spain.
  • Bajo-Grañeras R; Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas, Madrid, 28031, Spain.
  • Martín-Gutiérrez D; Department of Biochemistry and Molecular Biology, Instituto Universitario de Investigación Neuroquímica, Complutense University, Madrid, 28040, Spain.
  • Diez-Alarcia R; Instituto Ramón y Cajal de Investigación Sanitaria, Madrid, 28034, Spain.
  • Vilaró MT; Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas, Madrid, 28031, Spain.
  • Cortés R; Department of Biochemistry and Molecular Biology, Instituto Universitario de Investigación Neuroquímica, Complutense University, Madrid, 28040, Spain.
  • García-Font N; Instituto Ramón y Cajal de Investigación Sanitaria, Madrid, 28034, Spain.
  • Martín R; Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas, Madrid, 28031, Spain.
  • Espina M; Department of Biochemistry and Molecular Biology, Instituto Universitario de Investigación Neuroquímica, Complutense University, Madrid, 28040, Spain.
  • Botta J; Instituto Ramón y Cajal de Investigación Sanitaria, Madrid, 28034, Spain.
  • Ginés S; Department of Biochemistry and Molecular Biology, Instituto Universitario de Investigación Neuroquímica, Complutense University, Madrid, 28040, Spain.
  • McCormick PJ; Department of Pharmacology, University of the Basque Country/Euskal Herriko Unibertsitatea, Leioa, 48940, Spain.
  • Sánchez-Prieto J; Centro de Investigación Biomédica en Red de Salud Mental, Madrid, 28029, Spain.
  • Galve-Roperh I; Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas, Madrid, 28031, Spain.
  • Mengod G; Institut d'Investigacions Biomèdiques August Pi i Sunyer, Barcelona, 08036, Spain.
  • Urigüen L; Department of Neurosciences and Experimental Therapeutics, Institut d' Investigacions Biomèdiques de Barcelona, Consejo Superior de Investigaciones Científicas, Barcelona (IIBB-CSIC), 08036, Spain.
  • Marsicano G; Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas, Madrid, 28031, Spain.
  • Bellocchio L; Institut d'Investigacions Biomèdiques August Pi i Sunyer, Barcelona, 08036, Spain.
  • Canela EI; Department of Neurosciences and Experimental Therapeutics, Institut d' Investigacions Biomèdiques de Barcelona, Consejo Superior de Investigaciones Científicas, Barcelona (IIBB-CSIC), 08036, Spain.
  • Casadó V; Department of Biochemistry and Molecular Biology, Instituto Universitario de Investigación Neuroquímica, Complutense University, Madrid, 28040, Spain.
  • Rodríguez-Crespo I; Instituto de Investigación, Sanitaria del Hospital Clínico San Carlos, Madrid, 28040, Spain.
  • Guzmán M; Department of Biochemistry and Molecular Biology, Instituto Universitario de Investigación Neuroquímica, Complutense University, Madrid, 28040, Spain.
J Neurosci ; 41(38): 7924-7941, 2021 09 22.
Article em En | MEDLINE | ID: mdl-34353897
ABSTRACT
Cannabinoids, the bioactive constituents of cannabis, exert a wide array of effects on the brain by engaging Type 1 cannabinoid receptor (CB1R). Accruing evidence supports that cannabinoid action relies on context-dependent factors, such as the biological characteristics of the target cell, suggesting that cell population-intrinsic molecular cues modulate CB1R-dependent signaling. Here, by using a yeast two-hybrid-based high-throughput screening, we identified BiP as a potential CB1R-interacting protein. We next found that CB1R and BiP interact specifically in vitro, and mapped the interaction site within the CB1R C-terminal (intracellular) domain and the BiP C-terminal (substrate-binding) domain-α. BiP selectively shaped agonist-evoked CB1R signaling by blocking an "alternative" Gq/11 protein-dependent signaling module while leaving the "classical" Gi/o protein-dependent inhibition of the cAMP pathway unaffected. In situ proximity ligation assays conducted on brain samples from various genetic mouse models of conditional loss or gain of CB1R expression allowed to map CB1R-BiP complexes selectively on terminals of GABAergic neurons. Behavioral studies using cannabinoid-treated male BiP+/- mice supported that CB1R-BiP complexes modulate cannabinoid-evoked anxiety, one of the most frequent undesired effects of cannabis. Together, by identifying BiP as a CB1R-interacting protein that controls receptor function in a signaling pathway- and neuron population-selective manner, our findings may help to understand the striking context-dependent actions of cannabis in the brain.SIGNIFICANCE STATEMENT Cannabis use is increasing worldwide, so innovative studies aimed to understand its complex mechanism of neurobiological action are warranted. Here, we found that cannabinoid CB1 receptor (CB1R), the primary molecular target of the bioactive constituents of cannabis, interacts specifically with an intracellular protein called BiP. The interaction between CB1R and BiP occurs selectively on terminals of GABAergic (inhibitory) neurons, and induces a remarkable shift in the CB1R-associated signaling profile. Behavioral studies conducted in mice support that CB1R-BiP complexes act as fine-tuners of anxiety, one of the most frequent undesired effects of cannabis use. Our findings open a new conceptual framework to understand the striking context-dependent pharmacological actions of cannabis in the brain.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Encéfalo / Canabinoides / Transdução de Sinais / Receptor CB1 de Canabinoide / Neurônios GABAérgicos / Proteínas de Choque Térmico Tipo de estudo: Diagnostic_studies / Prognostic_studies Limite: Animals / Humans Idioma: En Revista: J Neurosci Ano de publicação: 2021 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Encéfalo / Canabinoides / Transdução de Sinais / Receptor CB1 de Canabinoide / Neurônios GABAérgicos / Proteínas de Choque Térmico Tipo de estudo: Diagnostic_studies / Prognostic_studies Limite: Animals / Humans Idioma: En Revista: J Neurosci Ano de publicação: 2021 Tipo de documento: Article